Emergency cardiovascular and neurological events are among the leading causes of morbidity and mortality worldwide. Rapid identification and treatment are essential to improving patient outcomes, yet many individuals struggle to recognize the signs of such emergencies, frequently hesitating to seek help until it is too late. The ECHAS application innovatively bridges this gap by leveraging smartphone technology to provide users with a virtual triage tool that mimics the initial diagnostic processes employed by emergency room physicians. The goal is simple yet profound: empower individuals to quickly assess their symptoms, understand the urgency, and seek immediate care if necessary.

The core functionality of ECHAS revolves around a symptom-driven algorithm designed to evaluate the likelihood of a stroke or heart attack. It incorporates a series of clinical questions derived from standard emergency room assessments that systematically screen for key indicators of cardiac and neurological distress. Additionally, the app integrates a finger-tapping test, a neurological exam designed to detect lateralized weakness often present in stroke patients. By quantifying motor function asymmetries alongside reported symptoms, the app enhances its predictive accuracy. Once the data are input, ECHAS calculates a risk score that categorizes the user’s condition and provides tailored recommendations ranging from calling emergency services to contacting a healthcare provider.

The initial clinical evaluation of ECHAS involved 202 patients presenting to an emergency department with symptoms suggestive of either stroke or heart attack. This real-world setting provided a rigorous test of the app’s diagnostic accuracy and usability. The cohort had an average age of 62 years, with a predominance of male patients and most identifying as white. This demographic provided valuable insights into the app’s performance across a typical population segment affected by these conditions. Results demonstrated that ECHAS achieved 100% sensitivity in identifying patients who ultimately required hospital admission following emergency evaluation, underscoring its potential as a reliable first-line screening tool.

Speed is a vital factor in emergent cardiovascular and cerebrovascular care. The “golden hour” concept in medicine underscores the window in which intervention can most dramatically alter patient outcomes, particularly for ischemic strokes and myocardial infarctions. During this critical interval, timely reperfusion therapies can minimize tissue necrosis and preserve neurological function. Notably, the ECHAS app was capable of identifying strokes within two minutes and heart attacks in only one minute, significantly expediting the decision-making process when seconds count. This rapid assessment capability aligns perfectly with clinical priorities and could drastically reduce pre-hospital delays.

The implications of ECHAS extend beyond mere detection; they encompass potential shifts in how emergency care is accessed and delivered. Presently, many patients delay or forgo emergency consultation due to uncertainty or misinterpretation of symptoms, which can lead to catastrophic outcomes. By providing an intuitive, easy-to-use interface on ubiquitous devices like smartphones and tablets, ECHAS democratizes access to life-saving information and encourages prompt action. The app’s design prioritizes usability to ensure even individuals without medical training can confidently navigate its assessment, fostering widespread adoption.

Despite these promising initial findings, researchers emphasize the need for larger-scale trials to validate ECHAS’s efficacy across diverse populations and clinical contexts. Given the variability of stroke and heart attack presentations depending on age, ethnicity, comorbidities, and socioeconomic factors, comprehensive evaluation is critical before the app’s integration into standard healthcare practices. Researchers have sought funding to expand testing within Virginia and beyond, collaborating with telehealth centers to explore implementation strategies that could maximize the app’s reach and impact.

The development of ECHAS reflects a growing trend in personalized and preventive medicine — harnessing digital tools to provide tailored interventions and empower patients in self-care. By facilitating early detection of life-threatening conditions, the app aligns with the broader objectives of translational medicine, which seeks to accelerate the translation of scientific research into practical clinical solutions. Beyond its diagnostic utility, ECHAS exemplifies how biometrics and digital health technology can intersect to revolutionize emergency medicine workflows.

From a technical standpoint, the algorithm underpinning ECHAS incorporates clinical decision support principles, utilizing symptom weighting and motor examination data to stratify risk. This diagnostic accuracy is reminiscent of traditional clinical scoring systems like the NIH Stroke Scale or the HEART score used in acute coronary syndrome. However, embedding these complex assessments into a user-friendly mobile platform represents a substantial innovation, overcoming limitations of accessibility and immediacy that have historically impeded early intervention.

This innovative project would not be possible without a multidisciplinary team of clinicians and biomedical engineers. Neurologists, cardiologists, public health experts, and software developers contributed to the app’s design, ensuring clinical validity and technical robustness. Dr. Jonathan R. Crowe, a neurologist at the University of Virginia and an author of the study, expressed optimism that ECHAS could transform emergency response by minimizing critical delays and ultimately saving lives. Support from seed investors and ongoing collaboration with UVA’s Center for Telehealth underscore a commitment to advancing this technology from pilot studies to widespread clinical adoption.

In conclusion, the ECHAS app embodies a promising fusion of digital innovation and clinical expertise aimed at addressing one of medicine’s most urgent challenges—rapid identification and treatment of strokes and heart attacks. Its initial clinical trial results highlight exceptional sensitivity and speed, suggesting a future where anyone with a smartphone could potentially diagnose a life-threatening emergency and facilitate timely intervention. As the developers pursue further validation and funding, the healthcare community and public alike anticipate how such technology might reshape emergency medical care paradigms, improving survival rates and neurological outcomes on a global scale.

Subject of Research: Detection of cardiac and neurological emergencies using mobile technology

Article Title: An app to detect heart attacks and strokes — and save lives

Web References: http://dx.doi.org/10.2196/60465

References: Dhand, A., Mangipudi, R., Varshney, A. S., Crowe, J. R., Ford, A. L., Sweitzer, N. K., Shin, M., Tate, S., Haddad, H., Kelly, M. E., Muller, J., Shavadia, J. S. (JMIR Formative Research)

Image Credits: UVA Health

The device functions through a microfluidic cartridge that collects saliva and utilizes a lateral flow assay embedded within a polymer lab-on-a-chip. Once the patient inserts this cartridge into a compact reader, the system quickly analyzes cortisol concentration, transmitting the data directly to smartphones or portable analyzers for immediate review. This capability is particularly transformative because it enables patients to conduct their own testing outside of clinical environments, facilitating real-time monitoring and convenient sharing of results with healthcare providers through web-based applications.

Mental health disorders, notably anxiety and depression, afflict over 400 million individuals worldwide and rank among the leading causes of disability globally. The hormone cortisol, often referred to as the “stress hormone,” plays a critical role in the body’s response to stress; however, sustained elevated cortisol levels have been closely linked to the pathophysiology of several mental health conditions. Traditional mental health assessments rely heavily on patient self-reporting, which can suffer from bias or underreporting. This new device provides an objective biochemical marker to supplement these evaluations, enhancing the precision of diagnoses.

The design combines microfabrication techniques with biochemical assay principles, integrating microchannels and sensitive detection reagents within a compact polymer chip. This enables rapid reaction kinetics and precise quantification of cortisol through lateral flow immunoassays, a method analogous in simplicity to common pregnancy tests but with advanced detection capabilities. The entire process from sample collection to result transmission is streamlined to take place within minutes, offering unprecedented speed for stress hormone profiling.

Co-author and doctoral candidate Supreeth Setty is expanding on this foundation by investigating dehydroepiandrosterone (DHEA), a hormone known to counterbalance the effects of cortisol. The ratio between cortisol and DHEA in saliva can serve as a more detailed biomarker for chronic stress conditions, providing clinicians nuanced insights into a patient’s endocrine status. This additional layer of testing could refine mental health assessments and help tailor personalized intervention strategies.

Setty emphasizes that the major advantage of point-of-care testing lies in its practicality and accessibility, reducing the delays typically associated with lab-based analyses. By furnishing immediate results, medical professionals can make quicker clinical decisions, which is vital in urgent mental health scenarios. Moreover, the objective data acts as a powerful supplement to psychometric questionnaires, often limited by patients’ variable self-awareness or reluctance to disclose symptoms.

The ongoing research efforts plan to move beyond prototype validation towards extensive clinical trials involving psychiatrists and mental health practitioners. Such collaborative endeavors aim to confirm the clinical utility of this platform in diverse patient populations, evaluating its accuracy, reproducibility, and overall impact on healthcare workflows. Success in these stages could pave the way for widespread adoption and integration into both primary care and specialized psychiatric services.

Interestingly, the researchers have also extended the principle of this technology to other critical biomarkers, notably cardiac troponin. Troponin levels rise sharply in the bloodstream following myocardial damage, a key diagnostic indicator of heart attacks. Through a similar point-of-care biochemical test capable of analyzing a single drop of blood, physicians could monitor cardiac health more continuously and respond swiftly to acute events, potentially improving patient outcomes by facilitating early interventions.

In addition, the UC team has ventured into infectious disease diagnostics by engineering a new testing platform aimed at rapid COVID-19 detection. Drawing from their experience in microfluidics and lateral flow assays, this platform enhances sensitivity and turnaround times, making it well suited for widespread screening applications during pandemics or localized outbreaks. The adaptability of their lab-on-a-chip approaches underscores the broad potential of their technological innovations across diverse fields of medical diagnostics.

Professor Chong Ahn highlights the urgent need for advances in mental health care technology, particularly given the increasing global burden of stress-related disorders. “Mental health care can be an urgent situation. And so these tests will help doctors make timely interventions,” he states. By empowering patients with tools for self-testing and enabling clinicians with objective biochemical data, these devices could revolutionize mental healthcare delivery, bridging gaps in accessibility and diagnostic precision.

The development of portable, user-friendly point-of-care platforms represents a paradigm shift from centralized laboratory testing towards decentralized, patient-centric health monitoring. Such advancements align with broader trends in digital health, personalized medicine, and telehealth services. As healthcare systems grapple with expanding demand and resource constraints, technologies like this lab-on-a-chip device offer scalable solutions that maintain clinical rigor while enhancing convenience.

Through continued innovation in microengineering and biosensing, the University of Cincinnati researchers are at the forefront of transforming how stress biomarkers are detected and leveraged clinically. Their combined expertise in engineering, chemistry, and clinical collaboration exemplifies the interdisciplinary approach needed to address complex health challenges. If successful, this innovation not only promises improved mental health diagnostics but also signals a new era in point-of-care biochemical testing that could impact multiple domains of medicine.

—

Subject of Research: Point-of-care biochemical testing for mental health and cardiac biomarkers using microfluidic lab-on-a-chip technology

Article Title: On-site analysis of cortisol in saliva based on microchannel lateral flow assay on polymer lab-on-a-chip

News Publication Date: 10-Apr-2025

Web References:
– https://link.springer.com/article/10.1007/s10544-025-00733-6
– https://pubs.acs.org/doi/full/10.1021/acs.analchem.4c06427
– https://pubs.rsc.org/en/content/articlelanding/2025/sd/d4sd00352g

Image Credits: Andrew Higley

Keywords: Psychiatry, Point-of-care testing, Lab-on-a-chip, Cortisol, Mental health diagnostics, Microfluidics, Stress biomarkers, Depression, Anxiety, Cardiac troponin, COVID-19 diagnostics